Gut Microbiome Results in Clinic: What to Act On

A patient came in last week with a bound stool test report, forty pages, colored bars, a gut health index. She wanted to know if her numbers were bad. I had no idea where to start.

Right. Two questions matter: is anything in that report a real finding, and is any of it actionable? The answer to both is more definite than you'd expect.

So what's the actual biology I need to know — why does the gut microbiome affect anything outside the gut at all?

It comes down to barrier integrity. The colon wall is three layers deep — a mucus layer, a single epithelial cell layer sealed by tight-junction proteins including claudins and occludin, then immune tissue underneath. When that holds, you're hosting a metabolically active microbial mass without systemic breach.

And when it doesn't hold?

Lipopolysaccharide — LPS, the outer-membrane component of Gram-negative bacteria — reaches portal and systemic circulation. It's a potent agonist at TLR4, which drives low-grade chronic innate immune activation. That's the plausible mechanism behind insulin resistance, hepatic steatosis, and endothelial dysfunction. But the evidence is mostly animal and mechanistic — the human data is associative, and LPS measurement in individuals is unreliable.

So when the report says 'leaky gut detected' and scores it, that's not a validated clinical finding?

Correct. The phenomenon is real; the individual measurement is not. No consumer stool panel has validated thresholds for intestinal permeability. That's a process measure, not a diagnosis.

What actually supports the barrier? Because the report recommends a proprietary probiotic blend, obviously.

Dietary fiber and fermented foods — that's the intervention class with the strongest randomized human evidence. A Stanford trial showed fermented food increased microbiome diversity and reduced inflammatory markers versus a high-fiber arm. Fiber feeds bacteria that produce butyrate — a short-chain fatty acid that is the primary energy source for colonocytes and supports tight-junction expression. That's solid mechanistic plus RCT-level evidence.

What about specific probiotics — not the proprietary blend, but named organisms?

Indication-specific only. Lactobacillus rhamnosus GG for pediatric antibiotic-associated diarrhea — guideline-supported. Saccharomyces boulardii for recurrent C. difficile in some guidelines. Beyond those narrow indications, evidence is weak or absent. The blend on the back of the report is marketed without trial evidence for the claims being made.

FMT — fecal microbiota transplant — where does that stand?

One established indication: recurrent C. difficile infection. FDA-approved products exist — Vowst and Rebyota. Everything else — IBD, metabolic disease — is trial-stage only. Don't offer it off that indication.

Are there drug interactions I should be anticipating at the prescribing stage?

Yes. Broad-spectrum antibiotics disrupt the microbiome durably — that's established. Proton pump inhibitors shift bacterial composition and increase small-intestinal bacterial overgrowth risk. Metformin alters the bile acid pool in ways that may contribute to its glycemic effect, per mechanistic and associative data. These don't change whether you prescribe, but they're worth noting when a patient reports GI symptoms on those drugs.

So when I'm actually sitting with that patient and her forty-page report, what do I tell her?

Tell her the report names organisms but lacks validated clinical thresholds, so colored bars don't translate to a diagnosis. Fiber and fermented foods have real evidence; the proprietary supplement does not. If she has symptoms — bloating, altered stool, recurrent infections — those warrant conventional workup, not a repeat microbiome panel.

Single thing you'd want me to walk away with?

The barrier is the clinical story. Butyrate from fiber supports it with real evidence. Everything else on that report is either a process measure or marketing until it has a validated threshold and a trial with a clinical endpoint.